Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 7.00M | 7.00M | 23.39M | 50.93M | 27.94M | 19.54M |
Gross Profit | 5.26M | 3.17M | 19.38M | 48.83M | 26.22M | -20.16M |
EBITDA | -357.95M | -326.98M | -130.42M | -60.40M | -48.54M | -33.96M |
Net Income | -306.31M | -274.48M | -112.96M | -54.81M | -47.53M | -32.27M |
Balance Sheet | ||||||
Total Assets | 1.10B | 1.12B | 649.32M | 387.97M | 381.35M | 298.27M |
Cash, Cash Equivalents and Short-Term Investments | 692.51M | 676.32M | 525.11M | 373.15M | 368.06M | 283.58M |
Total Debt | 25.97M | 19.17M | 2.87M | 3.48M | 5.18M | 6.72M |
Total Liabilities | 76.51M | 64.94M | 28.23M | 387.97M | 381.35M | 298.27M |
Stockholders Equity | 1.02B | 1.06B | 621.09M | 349.45M | 301.51M | 198.27M |
Cash Flow | ||||||
Free Cash Flow | -267.98M | -251.44M | -117.59M | -90.62M | -58.42M | 54.97M |
Operating Cash Flow | -264.11M | -247.58M | -115.22M | -87.17M | -55.78M | 55.46M |
Investing Cash Flow | -68.77M | -502.56M | -158.46M | -33.40M | -69.67M | -146.24M |
Financing Cash Flow | 354.58M | 677.55M | 362.72M | 97.17M | 145.45M | 128.75M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $3.14B | ― | -32.17% | ― | -25.85% | -23.89% | |
58 Neutral | $1.66B | ― | -5.78% | ― | 25.50% | 64.63% | |
58 Neutral | $2.05B | ― | -16.57% | ― | ― | ― | |
53 Neutral | $1.94B | ― | -31.34% | ― | -54.85% | -79.25% | |
52 Neutral | $2.01B | ― | -38.04% | ― | -82.38% | -164.76% | |
46 Neutral | C$194.28M | -4.22 | -8.60% | 2.64% | 13.54% | -1.44% | |
42 Neutral | $1.48B | ― | -69.30% | ― | ― | -68.13% |
On June 26, 2025, IDEAYA Biosciences appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer. This strategic appointment may influence the company’s financial management and operational strategies.
The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
On June 24, 2025, IDEAYA Biosciences held its Annual Meeting of Stockholders where three proposals were voted on. The election of two Class III directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation were addressed. The election saw Jeffrey L. Stein, Ph.D., and Scott W. Morrison nominated, with Stein receiving more votes. The ratification of the auditor was largely uncontested, and the executive compensation received a majority vote in favor, indicating shareholder support for the company’s leadership and financial oversight.
The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.